OPEN ORPHAN #ORPH – Result of AGM July 21, 2021 – Posted in: Blog, Open Orphan (ORPH)

21 July, 2021 Open Orphan plc (“Open Orphan”, the “Company”) Result of Annual General Meeting Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that at the Annual General Meeting held at 12 noon today, all resolutions were duly passed. For further information please contact: Open Orphan plc +353 (0) 1 644 0007 Cathal…

Open Orphan plc – Full Year Results June 24, 2020 – Posted in: Open Orphan (ORPH)

24 June 2020 Open Orphan plc (“Open Orphan” or the “Group”) Full Year Results for the year ended 31 December 2019 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is pleased to announce its full year results for the year ended 31 December 2019. Financial Highlights Open Orphan plc (As reported) hVIVO plc (As reported) Open…

Open Orphan presenting at Hardman & Co virtual Investor Forum on 9th July, 2020 June 17, 2020 – Posted in: Open Orphan (ORPH)

Hardman & Co Research: Open Orphan presenting at virtual Investor Forum on 9th July 2020 We are delighted to announce that Open Orphan will be presenting at our next Investor Forum on Thursday 9th July. The Investor Forum connects investors with companies looking for capital. Each company will present for 10-15 minutes, followed by an opportunity for Q&A. Open Orphan (ORPH) is a publicly traded company on the London AIM and Euronext Growth stock exchanges.…

Open Orphan – Positive Phase 1 study results published in The Lancet June 15, 2020 – Posted in: Open Orphan (ORPH)

Monday 15th June, 2020 Open Orphan plc (“Open Orphan” or the “Company”) Positive Phase I study results published in The Lancet Positive results from the Phase I study of the AGS-v vaccine developed by an Open Orphan joint venture, Imutex Limited, have been published in the peer reviewed journal The Lancet AGS-v is a first-in-class mosquito saliva, standalone, vaccine candidate designed to protect against mosquito-borne diseases carried in the saliva such as Zika, Malaria, Dengue Fever and…

Coronavirus vaccine: wanted — human guinea pigs to be infected with Covid-19 June 8, 2020 – Posted in: Open Orphan (ORPH)

Sabah Meddings Sunday June 07 2020, 12.01am, The Sunday Times Vaccine developers may have to resort to a method known as a ‘human challenge study’ KOEN VAN WEEL Scientists are applying for permission to infect healthy volunteers with Covid-19 amid fears the number of cases in the UK has fallen so steeply that it will be difficult to test potential vaccines. The health research company Hvivo, which runs a quarantine laboratory in east London, has…

Drug companies pay for exclusive access to UK genetic data September 12, 2019 – Posted in: Open Orphan (ORPH)

Dive Brief: Four of the world’s largest drug companies have agreed to pay around $120 million for exclusive access to genetic data on hundreds of thousands of people. Amgen, AstraZeneca, GlaxoSmithKline, and Johnson & Johnson will each have nine months to pour over the first wave of genomic data coming out of UK Biobank before the global research community gets a chance to look at it. That initial wave will be available at the end…

OPEN ORPHAN #ORPH – Result of AGM July 21, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc – Full Year Results June 24, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan presenting at Hardman & Co virtual Investor Forum on 9th July, 2020 June 17, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan – Positive Phase 1 study results published in The Lancet June 15, 2020 – Posted in: Open Orphan (ORPH)

Coronavirus vaccine: wanted — human guinea pigs to be infected with Covid-19 June 8, 2020 – Posted in: Open Orphan (ORPH)

Drug companies pay for exclusive access to UK genetic data September 12, 2019 – Posted in: Open Orphan (ORPH)

Address

Contact

Social

LEGAL